FDA approves new broad-spectrum sunscreen ingredient after 25 years

The U.S. Food and Drug Administration (FDA) has approved Bemotrizinol, also known as BEMT, a novel chemical compound for sunscreen. This marks the first approval of a new sunscreen ingredient in more than a quarter-century, signaling a significant advancement in sun protection technology for the American market.

BEMT stands out due to its broad-spectrum efficacy, providing protection against both UVA and UVB ultraviolet rays. Crucially, it is also more photostable than many current chemical filters, meaning it degrades less rapidly when exposed to sunlight. This enhanced stability translates to longer-lasting protection, reducing the need for frequent reapplication unless swimming or sweating.

“

This is great news that has been needed for a long time.

Dermatologists have welcomed the news. Dr. Gary Goldenberg told Women's Health, "This is great news that has been needed for a long time." He noted that the U.S. market had been "stuck in the past" while other regions, including Europe and Asia, already utilized more advanced and effective sunscreen formulas. The approval of BEMT is expected to enable the development of lighter, safer, and more protective sunscreens.

Unlike many existing U.S. chemical sunscreens that protect against only one type of UV ray (either UVA or UVB), requiring a combination of ingredients, BEMT offers comprehensive protection. Furthermore, studies indicate that BEMT is minimally absorbed into the bloodstream through the skin, addressing potential safety concerns. Its superior photostability means that sunscreens formulated with BEMT can offer more reliable and sustained defense against sun damage, including premature aging and skin cancer.

“

We were stuck in the past, when the rest of the world was already using more advanced formulas – lighter and safer sunscreens that offered better protection.